Table 1.

Patient eligibility criteria

Inclusion criteria	Exclusion criteria
Female, at least 19 years old	Patients with a history of receiving chemotherapy for cancer before this diagnosis was made
Patients diagnosed with primary breast cancer	Patients with symptoms of peripheral neuropathy that are severe and need to be immediately treated with surgical procedures or acute management
Patients with a diagnosis of CIPN presenting within the first week of an average pain score of at least 5 on a visual analogue scale of pain after completion of chemotherapy	Patients with pre-existing peripheral neuropathy due to trauma or intercurrent illness
Patients who do not take any medication to prevent or treat neuropathy before screening	Patients with skin inflammation at the attachment site
Patients with an ECOG performance status of 2 or less	Patients with a history of previous use of an acupressure wristband over a week. Patients with a history of cardiovascular disorders including the use of a pacemaker
Patients who are willing and able to comply with the requirements of the study	Patients with known hypersensitivity to metal or any medication
Patients who are willing and able to provide written informed consent	Patients with uncontrolled hypertension (systolic blood pressure ≥ 170 mmHg or diastolic blood pressure ≥ 100 mmHg) or uncontrolled diabetes
	Patients with hepatic insufficiency or dysfunction (three times higher than normal levels of ALT, AST, creatinine)
	Patients who were pregnant or are potentially pregnant and breastfeeding
	Patients with psychiatric disorders or who take medication for psychiatric illnesses
	Patients with a history of receiving investigative, new drugs within 4 weeks before enrollment
	Patients who do not have the ability to read, understand, or respond to questionnaires
	Patients with other reasons not to comply with this study protocol

CIPN chemotherapy-induced peripheral neuropathy, ECOG Eastern Cooperative Oncology Group, AST aspartate transaminase, ALT alanine aminotransferase